Utility of plasma tumour necrosis factor-α and transforming growth factor-β1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma

被引：9

作者：

Kumar, Sachin ^{[1
]}

Guleria, Randeep ^{[1
]}

Mohan, Anant ^{[1
]}

Singh, Vikas ^{[1
]}

Ali, Ashraf ^{[1
]}

Bharti, Alok C. ^{[2
]}

Das, Bhudev C. ^{[3
]}

机构：

[1] All India Inst Med Sci, Dept Med, New Delhi 110029, India

[2] Inst Cytol & Prevent Oncol, Div Mol Oncol, Noida, Uttar Pradesh, India

[3] Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India

来源：

BIOMARKERS | 2010年 / 15卷 / 05期

关键词：

Chemotherapy; diagnosis; prognosis; response; GROWTH-FACTOR; TNF-ALPHA; SERUM-LEVELS; CANCER-TREATMENT; PHASE-II; LINES; CYTOKINES; INTERFERON; EXPRESSION; THERAPY;

D O I：

10.3109/1354750X.2010.485699

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

We hypothesized that plasma level of tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta 1 may be a potential tool for diagnosis, prognosis and prediction of treatment outcome in non-small cell lung carcinoma (NSCLC). Plasma levels of TNF-alpha and TGF-beta 1 were quantified in 100 NSCLC patients and 100 controls. Association of TNF-alpha and TGF-beta 1 with response to therapy and survival was determined in 42 patients. An increased presence of TNF-alpha and TGF-beta 1 was observed in NSCLC compared with controls. TNF-alpha and TGF-beta 1 levels did not correlate with survival and response to chemotherapy. TNF-alpha and TGF-beta 1 do not appear to be reliable markers for predicting survival and response to therapy in advanced NSCLC.

引用

页码：446 / 453

页数：8

共 33 条

[1] Increased TGFβ1 plasma level in patients with lung cancer:: potential mechanisms [J].

Barthelemy-Brichant, N ;

David, JL ;

Bosquée, L ;

Bury, T ;

Seidel, L ;

Albert, A ;

Bartsch, P ;

Baugnet-Mahieu, L ;

Deneufbourg, JM .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 (03) :193-198

[2] VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer [J].

Dalaveris, Eleftherios ;

Kerenidi, Theodora ;

Katsabeki-Katsafli, Alexandra ;

Kiropoulos, Theodoros ;

Tanou, Kalliopi ;

Gourgoulianis, Konstantinos I. ;

Kostikas, Konstantinos .

LUNG CANCER, 2009, 64 (02) :219-225

[3] Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer [J].

Derin, Duygu ;

Soydinc, Hilat Oguz ;

Guney, Nese ;

Tas, Faruk ;

Camlica, Hakan ;

Duranyildiz, Derya ;

Yasasever, Vildan ;

Topuz, Erkan .

LUNG CANCER, 2008, 59 (02) :240-245

[4] Cytokines in cancer pathogenesis and cancer therapy [J].

Dranoff, G .

NATURE REVIEWS CANCER, 2004, 4 (01) :11-22

[5] Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians [J].

Enewold, Lindsey ;

Mechanic, Leah E. ;

Bowman, Elise D. ;

Zheng, Yun-Ling ;

Yu, Zhipeng ;

Trivers, Glenwood ;

Alberg, Anthony J. ;

Harris, Curtis C. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (01) :215-222

[6] Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients [J].

Guadagni, F ;

Ferroni, P ;

Basili, S ;

Facciolo, F ;

Carlini, S ;

Crecco, M ;

Martini, F ;

Spila, A ;

D'Alessandro, R ;

Aloe, S ;

Cerasoli, V ;

Del Monte, G ;

Mariotti, S ;

Mineo, TC ;

Roselli, M .

LUNG CANCER, 2004, 44 (03) :303-310

[7]

HONG WS, 1987, JPN J CLIN ONCOL, V17, P49

[8]

HSU S, 1994, CELL GROWTH DIFFER, V5, P267

[9] Targeting TGFβ signaling for cancer therapy [J].

Iyer, S ;

Wang, ZG ;

Akhtari, M ;

Zhao, WL ;

Seth, P .

CANCER BIOLOGY & THERAPY, 2005, 4 (03) :261-266

[10]

JAKOWLEW SB, 1995, CELL GROWTH DIFFER, V6, P465

← 1 2 3 4 →